New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 28, 2014
11:34 EDTVIVOMeridian receives Canadian licenses for two illumigene platforms
Meridian Bioscience announced that it has received medical device license approval from Health Canada to market two additional assays for use on their illumigene molecular diagnostic platform. With the addition of illumigene Mycoplasma and illumigene Pertussis, Meridian continues to expand its position in the Canadian market by providing innovative testing solutions that meet the needs of the clinical laboratory and drive improvements in patient care.
News For VIVO From The Last 14 Days
Check below for free stories on VIVO the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 24, 2014
08:17 EDTVIVOMeridian Bioscience reaffirms FY14 EPS view 85c-90c, consensus 88c
Reaffirms FY14 revenue view $190M-$195M, consensus $192.97M. Says financial condition is "sound."
08:16 EDTVIVOMeridian Bioscience reports Q3 EPS 21c, consensus 23c
Subscribe for More Information
July 22, 2014
07:08 EDTVIVOLife Sciences highlights this week at Canaccord
Canaccord highlighted six diagnostic names that report this week and recommends buying Top Pick IDEXX (IDXX) into the print given strong recurring razor/razorblade sales and consistent organic growth. The analyst expects Hold rated Quest Diagnostics (DGX) to report upside to Street estimates of $1.06/$1.882B, Quidel (QDEL) to have an uneventful report, Exact Sciences (EXAS) to provide an update on numerous catalysts near-term and Abaxis (ABAX) to report earnings below consensus. Lastly, the firm is cautious on Meridian Bioscience (VIVO) following a competitor report last week.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use